Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-β-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1156-1162

  Zhu, Hongxia ^a   Zhang, Guo ^a   Wang, Yan ^b   Xu, Ninghong ^c   He, Shun ^a   Zhang, Wei ^a   Chen, Meigui ^c   Liu, Mei ^a   Quan, Lanping ^a   Bai, Jingfeng ^a   Xu, Ningzhi ^a  

^a State Key Laboratory of Molecular Oncology   (China)

^b CANCER HOSPITAL   (China)

^c Loudi Centre Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SURVIVIN; T CELL FACTOR PROTEIN; T CELL FACTOR PROTEIN 4; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS;

EID: 77953190805     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01528.x     Document Type: Article

References (33)

1. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-68.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-82.
3. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008, 44:2806-12.
4. Morrison DK. Integrating signals from RTKs to ERK//MAPK. Oncogene 2007, 26:3113-21.
5. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-64.
6. Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer 2008, 8:129.
7. Asanuma H, Torigoe T, Kamiguchi K. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005, 65:11018-25.
8. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-9.
9. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70.
10. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci 2008, 99:1709-14.
11. Ryan BM, Konecny GE, Kahlert S. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006, 17:597-604.
12. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003, 362(9379):205-9.
13. Zhu H, Liu S, Zhou C. Anti-apoptosis gene survivin promotes cell growth and transformation. Zhonghua Yi Xue Za Zhi 2002, 82:338-40. Chinese
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-8.
15. Wang Y, Zhou X, Zhu H. Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway. Oncogene 2005, 24:6637-45.
16. Cuello M, Ettenberg SA, Clark AS. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001, 61:4892-900.
17. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-75.
18. Lee DH, Lee YJ. Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 2008, 105:546-53.
19. Graham TA, Weaver C, Mao F, Kimelman D, Xu W. Crystal structure of a beta-catenin/Tcf complex. Cell 2000, 103:885-96.
20. van Noort M, Clevers H. TCF transcription factors, mediators of Wnt-signaling in development and cancer. Dev Biol 2002, 244:1-8.
21. Xia W, Bisi J, Strum J. Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers. Cancer Res 2006, 66:1640-7.
22. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 2008, 14:4038-44.
23. Schroeder JA, Troyer KL, Lee DC. Cooperative induction of mammary tumorigenesis by TGFalpha and Wnts. Oncogene 2000, 19:3193-9.
24. Kanai Y, Ochiai A, Shibata T. c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 1995, 208:1067-72.
25. Shibata T, Ochiai A, Kanai Y. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 1996, 13:883-9.
26. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 2002, 277:22692-8.
27. Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B, Leonard EJ. Oncogenic Mutants of RON and MET Receptor Tyrosine Kinases Cause Activation of the β-Catenin Pathway. Mol Cell Biol 2001, 21:5857-68.
28. Duchesne C, Charland S, Asselin C, Nahmias C, Rivard N. Negative Regulation of beta -Catenin Signaling by Tyrosine Phosphatase SHP-1 in Intestinal Epithelial Cells. J Biol Chem 2003, 278:14274-83.
29. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303:1483-7.
30. Yan HX, He YQ, Dong H. Physical and functional interaction between receptor-like protein tyrosine phosphatase PCP-2 and beta-catenin. Biochemistry 2002, 41:15854-60.
31. Tapia JC, Torres VA, Rodriguez DA, Leyton L, Quest AF. Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci U S A 2006, 103:15079-84.
32. Xia W, Bacus S, Hegde P. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006, 103:7795-800.
33. Aird KM, Ding X, Baras A. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther 2008, 7:38-47.